BioNTech SE BNTX reported Q1 FY23 revenues of €1.28 billion, down from €6.37 billion a year ago, mainly due to lower commercial revenues from the supply and sales of the company's COVID-19 vaccines worldwide.
The company posted Q1 diluted EPS of €2.05, down from €14.24 a year ago.
The company says the COVID-19 vaccine franchise is focused on vaccine adaptation readiness ahead of the fall season and advancing next-generation vaccine candidates and combinations.
"In the first quarter of 2023, we expanded our toolkit of cutting-edge technologies to new modalities and added a novel immune checkpoint inhibitor candidate targeting CTLA-4 and two investigational antibody-drug conjugates to our arsenal against cancer," said Ugur Sahin said, CEO & Co-Founder.
"For the remainder of 2023, we are focused on advancing our disruptive platforms against solid tumors and accelerating clinical programs in infectious diseases of high global need," Sahin added.
Outlook: BioNTech reiterates FY23 COVID-19 vaccine revenue of approximately €5 billion compared to €17.1 billion in 2022.
Price Action: BNTX shares are up 3.57% at $112.30 during the premarket session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.